Canaccord analyst John Newman initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with an Outperform at Citizens JMP
- Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
- Compass Therapeutics Reports Q3 2025 Financial Results
- Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
- Compass Therapeutics reports Q3 EPS (8c), consensus (13c)